ARCTArcturus Therapeutics Holdings Inc.

$210M

Q2 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$27M+1254.0% YoY

Gross Profit

-$11M-41.0% margin

Operating Income

-$22M-81.5% margin

Net Income

-$22M-79.6% margin

EPS (Diluted)

$-0.82

QoQ Revenue Growth

+416.6%

Cash Flow

Operating Cash Flow

-$37M

Free Cash Flow

-$36M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$337M

Total Liabilities

$166M

Stockholders' Equity

$171M

Cash & Equivalents

$283M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$27M	$2M	+1254.0%
Gross Profit	-$11M	-$44M	+74.6%
Operating Income	-$22M	-$54M	+58.9%
Net Income	-$22M	-$55M	+60.5%

ARCT Q2 2022 Earnings — Arcturus Therapeutics Holdings Inc. Revenue & Financial Results | Market Cap Arena